LYTIR

Company · RARE

Ultragenyx Pharmaceutical Inc.

Nasdaq's symbol directory lists RARE on Nasdaq as “Ultragenyx Pharmaceutical Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 7 occasions ($542K); 1 planned-sale notice; 9 filings by holders of 5% or more; 3 congressional trade disclosures; 5 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $542K in total.Jun: Insider sales $97KJul: Insider sales $156KAug: Insider sales $164KSep: Insider sales $17KOct: Insider sales $108KDecJanFebMarAprMayJunJulAugSepOctNov$164K
Insider purchases above the line: $0Insider sales below: $542K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Horn Howard, Chief Financial Officer sold on 3 days 2 of them under a 10b5-1 plan latest Oct 15, 2026 sold $381K
  2. Parschauer Karah Herdman, EVP and Chief Legal Officer sold on 2 days all under a 10b5-1 plan latest Aug 3, 2026 sold $94K
  3. Sanders Corazon (Corsee) D. sold on 1 day latest Jun 15, 2026 sold $50K
  4. Huizenga Theodore Alan, SVP, Chief Accounting Officer sold on 1 day all under a 10b5-1 plan latest Sep 15, 2026 sold $17K
Every trade (7)
  1. SELLHorn Howard, Chief Financial Officer sold Oct 15, 2026 7,066 shares filing $108K
  2. SELLHuizenga Theodore Alan, SVP, Chief Accounting Officer sold Sep 15, 2026 1,283 shares 10b5-1 plan (scheduled) filing $17K
  3. SELLHorn Howard, Chief Financial Officer sold Aug 3, 2026 4,696 shares 10b5-1 plan (scheduled) filing $117K
  4. SELLParschauer Karah Herdman, EVP and Chief Legal Officer sold Aug 3, 2026 1,900 shares 10b5-1 plan (scheduled) filing $47K
  5. SELLHorn Howard, Chief Financial Officer sold Jul 1, 2026 4,698 shares 10b5-1 plan (scheduled) filing $156K
  6. SELLSanders Corazon (Corsee) D. sold Jun 15, 2026 2,000 shares filing $50K
  7. SELLParschauer Karah Herdman, EVP and Chief Legal Officer sold Jun 15, 2026 1,899 shares 10b5-1 plan (scheduled) filing $47K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. THEODORE HUIZENGA filed Sep 15, 2026 Officer 1,283 shares planned sale date 09/15/2026 filing $17K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. AQR Capital Management, LLC filed Nov 13, 2026 Schedule 13G/A passive 633,393 shares filing 0.64%
  2. STATE STREET CORPORATION filed Nov 10, 2026 Schedule 13G passive 7,538,078 shares filing 7.6%
  3. Vanguard Portfolio Management filed Oct 30, 2026 Schedule 13G/A passive 8,481,266 shares filing 8.6%
  4. Madison Avenue International LP filed Oct 20, 2026 Schedule 13G passive filing 6.4%
  5. RTW Investments, LP filed Aug 14, 2026 Schedule 13G passive filing 7.9%
  6. AQR Capital Management, LLC filed Aug 13, 2026 Schedule 13G passive 6,560,809 shares filing 6.66%
  7. STATE STREET CORPORATION filed Aug 7, 2026 Schedule 13G passive 6,158,766 shares filing 6.3%
  8. VANGUARD PORTFOLIO MANAGEMENT LLC filed Jul 31, 2026 Schedule 13G/A passive 6,853,427 shares filing 6.95%
  9. Vanguard Capital Management filed Jul 31, 2026 Schedule 13G passive 5,058,419 shares filing 5.13%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Sep 29, 2026 reported Oct 12, 2026 one of 57 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Mar 3, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  3. Gilbert Cisneros (D-CA31): Purchase Feb 18, 2026 reported Mar 9, 2026 one of 85 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Completion of acquisition or disposition of assets; Results of operations and financial condition; Costs associated with exit or disposal activities filing Nov 3, 2026
  2. Other events filing Oct 19, 2026
  3. Entry into a material definitive agreement filing Oct 14, 2026
  4. Entry into a material definitive agreement filing Oct 7, 2026
  5. Other events filing Sep 17, 2026

Lobbying · Senate LDA reports

Lobbying filed

4 quarterly lobbying reports for 2026 naming Ultragenyx Pharmaceutical Inc. as the client: 1 filed by the company itself, 3 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. The company itself Q1 2026 filing $440K
  2. MEHLMAN CONSULTING, INC. Q1 2026 filing $60K
  3. MILLER STRATEGIES, LLC Q1 2026 filing no amount stated
  4. MILLER STRATEGIES, LLC Q1 2026 filing no amount stated

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.